Close
Patheon
  • 8 FEBRUARY 2016

    Patheon Appoints Andrew G. Long as Senior Vice President and Global Business Controller

    Dateline City:
    DURHAM, N.C.

    DURHAM, N.C.--(BUSINESS WIRE)--Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, has hired Andrew G. Long as senior vice president and global business controller. Long will report to Stuart Grant, chief financial officer for Patheon, and will be based at the company’s headquarters in Durham, N.C.

    Long will focus on Patheon’s financial planning and performance management tools and processes, in support of the company’s position as a category leader in the pharma services industry.

    He brings more than 25 years of experience to Patheon. He most recently served as vice president, global finance of the Fisher Scientific Group for Thermo Fisher Scientific, a biotechnology product development company, where he was responsible for global financial planning and analysis, controllership, mergers and acquisitions and strategic planning.

    “Andy is a great addition to our organization, said Grant. “He is a seasoned professional with vast experience in all aspects of finance. We will benefit from his experience as we advance our business strategy.”

    Prior to joining Thermo Fisher, Long was vice president, worldwide finance and supply chain management at Cambrex Corporation, responsible for global financial planning, reporting and analysis for a division with 14 manufacturing and distribution sites across 10 countries. Previously, Long served in a number of roles of increasing responsibility for companies including Eaton Corporation, Emerson Electric and Abbott Laboratories.

    “I am very pleased to join Patheon,” said Long. “The company is widely recognized as a market leader with a solid growth profile.”

    Long holds a Bachelor of Science from Indiana University and a Master of Business Administration from the Kellogg Graduate School of Business, Northwestern University.

    About Patheon

    Patheon is a leading global provider of pharmaceutical development and manufacturing services. With approximately 8,700 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. www.patheon.com

    Language:
    English
    Contact:

    Patheon
    Mari Mansfield, 919-226-3137
    Mari.Mansfield@Patheon.com
    media@patheon.com

    @patheon

    Andrew Long named SVP and global business controller for Patheon

    ... Read more
  • 2 FEBRUARY 2016

    Patheon Appoints Leader for Biologics

    Dateline City:
    DURHAM, N.C.

    Industry Veteran, Steve Lam, to Direct Rapidly Expanding Business

    DURHAM, N.C.--(BUSINESS WIRE)--Patheon today announced the appointment of Steve Lam as senior vice president of the company’s biologics business. Lam will report to Lukas Utiger, president of the company’s Drug Substance Services (DSS) segment, effective immediately. Biologics is a fast-growing area of the industry, which requires experience and expertise because of their complexity.

    For the past 18 years, Lam has served as vice president of operations for Amgen, one of the world's leading independent biotechnology companies. He led a company-wide transformation initiative driving robust quality management processes and operational excellence. He brings to Patheon more than 25 years of leadership experience in biopharmaceutical operations with a focus on manufacturing and commercializing human therapeutics. He has specific expertise in protein manufacturing, cGMP compliance, quality systems and technology transfer.

    “Our biologics business is an area with tremendous growth potential for Patheon,” said Utiger. “With Steve’s experience and his broad client perspective, he will energize our efforts and support our biopharmaceutical clients who are looking for a knowledgeable partner with scale and expertise to meet their needs. He will help us to continue to pursue strategies that capitalize on this expanding area of our business.”

    Lam’s experience includes responsibility for lean manufacturing transformation and driving efforts toward greater efficiency. His efforts to improve manufacturing strategy, reduce risk and enhance product quality resulted in increased revenue while providing Amgen with new capabilities.

    Lam earned a Bachelor of Arts degree in chemistry from Knox College in Galesburg, Illinois. He also attended the Executive Development Program at Northwestern University in Evanston, IL. He will be based at Patheon’s offices in Boston.

    About Patheon

    Patheon is a leading global provider of outsourced pharmaceutical development and manufacturing services. With approximately 8,700 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. www.patheon.com

    Language:
    English
    Contact:

    Patheon
    Mari Mansfield, 919-226-3137
    Mari.Mansfield@Patheon.com
    media@patheon.com

    @Patheon

    Steve Lam, an industry veteran, will head Patheon's biologics business

    ... Read more
  • 11 JANUARY 2016

    Life Sciences Executive to Join Patheon

    Dateline City:
    DURHAM, N.C.

    Gilles Cottier to lead the company’s PDS business

    DURHAM, N.C.--(BUSINESS WIRE)--Patheon announced today the appointment of Gilles Cottier as president of the company’s pharmaceutical development services (PDS) division effective immediately. He will serve as a member of Patheon’s executive committee and will report to Patheon CEO James Mullen.

    The appointment of Cottier is part of a larger realignment effort by the company to create three distinct business segments – drug product services (DPS), drug substance services (DSS) and PDS. This will help the company forge deeper relationships with clients and employ new business models to help clients simplify their supply chain management activities. Patheon’s three business segments are led by key executives: Franco Negron for DPS, Lukas Utiger for DSS and now Cottier for PDS.

    Cottier will assume the responsibilities for the PDS business from Michael Lehmann who was leading both Global PDS and Global Sales and Marketing. Lehmann will now focus on the Sales and Marketing function to support the expanding number of new business opportunities and increasing complexity of client relationships.

    “Gilles brings a wealth of relevant experience in the life science and technology sector, including the manufacture of chemical and biochemical compounds, contract manufacturing and commercial services,” said Mullen. “I’d also like to thank Mike Lehmann for his outstanding leadership of the PDS business during his tenure. We established ourselves as the global market leader of PDS services.”

    Cottier joins Patheon from Sigma-Aldrich Corporation where he was executive vice president and president of the Sigma-Aldrich Fine Chemicals (SAFC) Commercial Unit overseeing the contract manufacturing and the commercial services business unit which achieved more than $700 million in sales in 2014.

    Cottier held numerous positions of increasing responsibility at Sigma-Aldrich during his more than 25 years with the company. He earned a master’s degree in organic chemistry from the Ecole Supérieure de Chimie Industrielle de Lyon, France and advanced management program from the Harvard Business School in Boston, MA.

    About Patheon

    Patheon is a leading global provider of outsourced pharmaceutical development and manufacturing services. With approximately 8,700 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. www.patheon.com

    Language:
    English
    Contact:

    Patheon
    Mari Mansfield, 919-226-3137
    Mari.Mansfield@Patheon.com
    media@patheon.com

    ... Read more
  • 22 OCTOBER 2015

    Patheon to Highlight Solubility Solutions and Patheon OneSource™ at 2015 AAPS Annual Meeting and Exposition

    Company to present 17 posters on a range of topics from validation of stability to process optimization Experts from Patheon (http://www.patheon.com/), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, will present on a breadth of industry topics at the 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, being held Oct. 25-29 in Orlando, Fla. Marshall Crew, vice president of global PDS scientific excellence, will deliver a presentation titled, “Improving Poor Solubility ... Read more
  • 5 OCTOBER 2015

    Patheon to Highlight Flexible Capacity Solutions and Solubilization at CPhI/ICSE Worldwide 2015

    Patheon’s Marshall Crew, Ph.D., and Joe Principe to present in the Speaker’s Corner on Oct. 14 Patheon (http://www.patheon.com/), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, will be on site at the 26th Annual CPhI/ICSE Worldwide conference from , Oct. 13 -  Oct. 15, in Madrid. Two noted Patheon experts will present at the Speaker’s Corner on Wednesday, Oct. 14. At noon, Marshall Crew, Ph.D. and vice president, global PDS scientific excellence, will discuss how to optimize solubilization strategies and ... Read more
  • 28 SEPTEMBER 2015

    Patheon Unveils New Brand and Identity

    “A Healthier World. Delivered.™” Reflects Company’s Focus on Helping Customers Deliver Life-changing Medications Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, today unveiled its new brand identity, reflecting the company’s leadership position in the pharmaceutical services industry, and the difference it makes in the lives of patients. The new brand positioning centers around an updated brand promise based on the fundamental belief; the world would be a healthier place if tomorrow’s medicines were ... Read more
  • 22 JULY 2015

    ARDIAN ACQUIRES EXCLUSIVE SYNTHESIS (ES) AND MALEIC ANHYDRIDE INTERMEDIATES & SPECIALTIES (IM) BUSINESS FROM DPx HOLDINGS B.V.

    Ardian, together with current management, to acquire agrochemicals (ES) and fine chemicals (IM) business activities of DPx Holdings B.V. to gain full independence, expand product portfolio and further international growth Ardian, the independent private investment company, today announces the acquisition of the Exclusive Synthesis (ES) and Maleic Anhydride Intermediates & Specialties (IM) business activities, based in Linz, Austria, of DPx Holdings B.V. The parties have agreed not to disclose details of the transaction. The completion of the transaction is still subject to approval by the ... Read more
  • 21 JULY 2015

    LIVIA Group acquires Patheon Facility in Capua, Italy

    LIVIA Group, a German-based industrial holding, has entered into an agreement to acquire the Capua manufacturing facility and associated employees from Patheon, a leading global provider of outsourced contract development and manufacturing (CDMO) services for the pharma and biopharma industries. Capua, one of the world’s largest independent microbial fermentation-based manufacturing facilities with 1,400m³ fermentor capacity, represents an exceptional investment opportunity for LIVIA in the highly attractive market of enzymes and small molecules. “LIVIA Group is enthusiastic about ... Read more
  • 15 JUNE 2015

    Patheon Announces Biologics Deal with Inhibrx

    Patheon (http://www.patheon.com/), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, has entered into a development contract with Inhibrx, abiologic immunotherapeutic company focused on high, unmet medical needs in oncology, infectious disease and inflammatory conditions. As part of the agreement, Patheon will develop production processes at its Princeton, N.J., facility and will manufacture products at its Brisbane, Australia, location in support of a pipeline of future programs with Inhibrx. The initial ... Read more
  • 11 JUNE 2015

    Patheon to Exhibit Biologics Services and Expertise at 2015 BIO International Convention

    Patheon (http://www.patheon.com/), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, will showcase ways to accelerate biologic process development and funding options for biopharmaceutical programs at the BIO International Convention in Philadelphia, from Tuesday, June 16, to Wednesday, June 17.    Two of Patheon’s biologics rapid development and scale-up experts, Matt Caple, scientific director, cell culture development, and Tertia Dex, director, business development, will offer exclusive scientific ... Read more
  • 8 JUNE 2015

    Patheon Files Registration For Initial Public Offering

    Patheon, a leading global provider of outsourced pharmaceutical development and manufacturing services through its end-to-end integrated service offering,  today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. J.P. Morgan, Morgan Stanley, Jefferies and UBS will act as joint book-running managers for the proposed offering. The proposed offering will be ... Read more
  • 27 MAY 2015

    Patheon Scientist Dr. Marshall Crew Named to Medicine Maker Power List 2015

    Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that Dr. Marshall Crew, vice president, global PDS scientific excellence, has been named one of the top 100 most influential people in drug development and manufacture by the publication The Medicine Maker.  Dr. Crew, an elite scientist and expert in low-solubility drug formulation, was previously CEO and founder of Agere Pharmaceuticals, a CDMO specializing in oral bioavailability of insoluble molecules that was recently acquired by ... Read more
  • 13 MAY 2015

    Patheon to Sponsor Webinar on Assessing Stability for Shipment of API and Drug Products

    Analytical development experts will address questions about regulatory requirements, and stability and shipping studies in a complimentary webinar this month sponsored by Patheon (http://www.patheon.com/), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries. Hosted by Pharmaceutical Technology, a comprehensive information source for professionals in the global pharmaceutical manufacturing drug development community, the webinar “Stability Assessment for Shipment of API and Drug Products,” will provide guidance on ... Read more
  • 12 MAY 2015

    Patheon Expands Stability Testing Capabilities in Greenville, NC

    Company Invests $3 million in Equipment and Talent in its Centralized Stability Testing Lab Patheon (http://www.patheon.com/), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, is investing more than $3 million to expand its Greenville, N.C. site’s stability testing capabilities. The expansion includes the addition of the most advanced automated systems and the assembly of a highly experienced scientific team to enhance its centralized stability lab offerings. Since 2011, more than 1,000 stability studies with ... Read more
  • 29 APRIL 2015

    JLL/Delta Dutch Pledgeco B.V. Announces Pricing of its Private Placement of $550 Million 8.75% / 9.50% Senior PIK Toggle Notes due 2020

    JLL/Delta Dutch Pledgeco B.V. (the “Company”), the parent company of DPx Holdings B.V., announced today the pricing of the previously announced private offering of $550 million aggregate principal amount of its 8.75% / 9.50% Senior PIK Toggle Notes due 2020 (the “Notes”). The total size of the offering of the Notes has been increased from $500 million to $550 million. The Company intends to use the net proceeds from the offering of the Notes to pay a dividend or other distribution to its parent company and certain related transaction fees and expenses related to the offering. The ... Read more
  • 29 APRIL 2015

    JLL/Delta Dutch Pledgeco B.V. Announces Offering of $500 Million Senior PIK Toggle Notes due 2020

    JLL/Delta Dutch Pledgeco B.V. (the “Company”), the parent company of DPx Holdings B.V., announced today the commencement of a private offering of $500 million aggregate principal amount of its Senior PIK Toggle Notes due 2020 (the “Notes”). The Company intends to use the net proceeds from the offering of the Notes to pay a dividend or other distribution to its parent company and certain related transaction fees and expenses related to the offering. The offering of the Notes will be made in a private transaction in reliance upon an exemption from the registration requirements of the ... Read more
  • 16 APRIL 2015

    Patheon Scientist to Give Keynote Address at Lyophilisation USA Conference

    A top scientific expert at Patheon (http://www.patheon.com/), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, will be the keynote speaker at this year's Lyophilisation USA Conference (https://www.smi-online.co.uk/pharmaceuticals/northamerica/conference/lyophilisation-usa?elqTrackId=F9237EDD6EBABCE5A93C4B66B65A2C37), Wednesday, April 29, through Thursday, April 30, at the Renaissance Woodbridge Hotel in Iselin, N.J. Ronald Pate, lyophilization development scientist, will present, "Cycle Development Basic ... Read more
  • 10 APRIL 2015

    Patheon to Participate in Industry Panels and Feature Patheon OneSourceTM at INTERPHEX

    Patheon (http://www.patheon.com/), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, will showcase its broad set of development and manufacturing services, and the company’s integrated offering at INTERPHEX in New York City from Tuesday, April 21, to Thursday, April 23. Company leaders will offer industry insights during key panel discussions sponsored by the Pharma and BioPharma Outsourcing Association. Franco Negron, senior vice president of drug product services in North America for Patheon, will ... Read more
  • 1 APRIL 2015

    Patheon Closes Acquisition of IRIX Pharmaceuticals

    Patheon (http://www.patheon.com/), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, has closed the previously announced transaction to acquire IRIX Pharmaceuticals, a Florence, S.C.-headquartered  company that specializes in making difficult to manufacture Active Pharmaceutical Ingredients (API) for drugs from early and late development, through commercial launch. With the acquisition, Patheon establishes a North American presence for comprehensive API development and manufacturing to address customers’ most ... Read more
  • 20 MARCH 2015

    Patheon Closes Acquisition of Agere Pharmaceuticals

    Patheon (http://www.patheon.com/), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, has closed the previously announced transaction to acquire Agere Pharmaceuticals, Inc., a privately-held CDMO, that specializes in improving the absorption rate of medications (bioavailability). The company will become part of Patheon’s pharmaceutical development services unit and operate as a solubility center of excellence in Bend, Ore. ... Read more
  • 12 MARCH 2015

    Patheon Leaders to Attend DCAT Week

    Durham, N.C.  — (March 11, 2015) Patheon (http://www.patheon.com/), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sector, will participate at DCAT Week 2015 in New York, March 16-19. Patheon recently announced two acquisitions in support of the company’s business strategy to enter into logical adjacencies and drive industry consolidation. Patheon offerings now include North American API development and manufacturing services with the addition of IRIX Pharmaceuticals and a solubility center of excellence with the ... Read more
  • 10 MARCH 2015

    Patheon Expands Comprehensive Active Pharmaceutical Ingredient Services with Acquisition of IRIX Pharmaceuticals

    Number One Provider of Pharmaceutical Development Services Establishes Strong API Presence in U.S. Patheon (http://www.patheon.com/), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, announced it has reached a definitive agreement to acquire IRIX Pharmaceuticals, a company headquartered in Florence, S.C., that specializes in difficult to manufacture Active Pharmaceutical Ingredient (API) needs for drugs from early and late development, through commercial launch. Patheon will purchase IRIX and expects to close the ... Read more
  • 9 MARCH 2015

    Patheon Adds Complex Solubility Expertise with Acquisition of Agere

    Number One Provider of Pharmaceutical Development Services to Establish Global Solubility Center of Excellence in Western United States Patheon (http://www.patheon.com/), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, has reached a definitive agreement to acquire Agere Pharmaceuticals, a privately held CDMO, headquartered in Bend, Ore., that specializes in improving the absorption rate of medications (bioavailability). Agere is a recognized leader in helping customers improve the delivery of their medications ... Read more
  • 3 MARCH 2015

    Patheon to Host Strategy Seminar for Emerging Companies

    Industry-leading experts will discuss key strategies for early product development at a seminar this month hosted by  Patheon (http://www.patheon.com/)®, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors. The event “API Supply: Key Strategies for Creating Value in Early-Stage Development,” which looks to address challenges in API development and drug formulation for emerging companies will be held Thursday, March 19, at the Embassy Suites Airport-Waterfront in San Francisco from 11:30 a.m. to 3:30 p.m. Experts ... Read more
  • 24 FEBRUARY 2015

    Patheon Cincinnati Regional Operations Recognized for Green Business Initiatives

    Patheon (http://www.patheon.com/), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, will be honored as a finalist for the Green Business Award by the Cincinnati Business Courier for its outstanding leadership in sustainable practices, at the Sixth Annual Green Business Awards Program on Thursday, March 5 at 5:30 p.m., at the Sharonville Convention Center in Cincinnati. Patheon is one of several organizations to be honored for sustainable buildings, practices, products and advocacy. “We are thrilled to be ... Read more
  • 20 FEBRUARY 2015

    Patheon to Present at 2015 J.P. Morgan Global High Yield and Leveraged Finance Conference

    Patheon (http://www.patheon.com/), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, announced today that James C. Mullen, CEO, will present an update on the company’s financial standing at the J.P. Morgan Global High Yield and Leveraged Finance Conference at the Loews Miami Beach Hotel in Miami, on Monday, Feb. 23 at 4 p.m. ... Read more
  • 17 FEBRUARY 2015

    Patheon Customers Save Up to Six Months of Development Time with New Filling Technology

    Patheon Introduces Xcelodose® Automated Encapsulator Technology at Milton Park, U.K. Facility Patheon (http://www.patheon.com/), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, has added a new filling technology that significantly reduces the time needed for formulation development and stability testing at its Milton Park, U.K., facility. The Xcelodose® 600 S Automated Encapsulator, supports early phase development for oral dose products.       This technology adds to the site’s breadth of services, from early ... Read more
View More